Loading...
•
Sep 30, 2024
TransMedics Q3 2024 Earnings Report
Reported third quarter financial results, demonstrating significant revenue growth and a return to profitability.
Key Takeaways
TransMedics reported a strong third quarter with a 64% increase in revenue compared to the previous year, driven by increased utilization of the Organ Care System and logistics services. The company achieved net income of $4.2 million, a significant improvement from the net loss in the same quarter of the previous year. TransMedics is on track to meet its target of 10,000 OCS transplant cases per year in the U.S. by 2028 and expects full-year revenue to be in the range of $425 million to $445 million.
Total revenue reached $108.8 million, a 64% increase year-over-year.
Net income was $4.2 million, or $0.12 per diluted share.
The company owned 18 total aircraft as of September 30, 2024.
Full year 2024 revenue is expected to be in the range of $425 million to $445 million.
Revenue by Segment
Forward Guidance
TransMedics continues to expect revenue for the full year 2024 to be in the range of $425 million to $445 million, which represents 76% to 84% growth compared to the company's prior year revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...